Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too

The Ministry of Health, Labor and Welfare (MHLW) is eyeing a tweak to a dosage-related drug re-pricing rule, which would subject Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) to a 56% cut from its initial NHI price - or a price...read more